• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNexus Gene Lab Corp - Common stock (NQ:BGLC)

1.201 -0.020 (-1.63%)
Delayed Quote Updated: 1:25 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,982
Open 1.210
Bid (Size) 1.010 (100)
Ask (Size) 1.430 (600)
Prev. Close 1.221
Today's Range 1.201 - 1.244
52wk Range 1.070 - 5.888
Shares Outstanding 1,796,507
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
BioNexus to Build AI Applications for Malaysian Healthcare Under Exclusive CogniAI Licence
October 07, 2026
Licence of up to 20 years, payable in shares, as Malaysia commits RM1 billion to digitalizing public healthcare 
From BioNexus Gene Lab Corp.
Via GlobeNewswire
News headline image
RYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene Lab
October 05, 2026
License of up to 20 years and reciprocal share exchange would entitle RYET to a 10% royalty on qualifying technology receipts and 560,000 BGLC shares as Malaysia accelerates public healthcare... 
From Ruanyun Edai Technology Inc.
Via GlobeNewswire

Performance

52-Week Range 79.6% below 52-week high
1.201
1.0752W Low 5.8952W High
1 Week 13.6% below 1-week high
1.191W Low 1.391W High

BioNexus Gene Lab Corp - Common stock (BGLC) traded between $1.07 and $5.89 over the past 52 weeks and last traded at $1.20, 79.6% below its 52-week high. Over the past week it ranged between $1.19 and $1.39.

Past 12 Months
-13.6%
-18.6%
-28.1%
-47.3%
-69.5%
-76.6%
1W -$0.19
1M -$0.27
3M -$0.47
6M -$1.08
YTD -$2.74
1Y -$3.93

BGLC was -76.6% over the past year, -47.3% over six months, -69.5% year to date, -13.6% in the last week.

12 Months vs Market
BGLC
-76.6%
DIA
+12.4%
SPY
+14.9%
QQQ
+17.5%
IWM
+11.1%

Over the past 12 months BGLC returned -76.6% versus DIA (Dow) +12.4%, SPY (S&P 500) +14.9%, QQQ (Nasdaq 100) +17.5% and IWM (Russell 2000) +11.1%.

Volume & Liquidity 0.61× 3-mo avg
Today 6,982 3-mo avg 11.5K
1W
9.3K
1M
10.1K
3M
11.5K
6M
55.7K
YTD
41.6K
1Y
66.4K

BGLC most recently traded 6,982 shares against a 3-month average daily volume of 11.5K.

More News

Read More
News headline image
BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit
July 28, 2026
From BioNexus Gene Lab Corp.
Via GlobeNewswire
News headline image
BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development
May 29, 2026
From BioNexus Gene Lab Corp.
Via GlobeNewswire
News headline image
BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform
March 11, 2026
From BioNexus Gene Lab Corp.
Via GlobeNewswire
News headline image
BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman
February 23, 2026
From BioNexus Gene Lab Corp.
Via GlobeNewswire
News headline image
BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN’s Multi-Billion Dollar Market
January 28, 2026
From BioNexus Gene Lab Corp.
Via GlobeNewswire
News headline image
BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard™
December 03, 2025
From BioNexus Gene Lab Corp.
Via GlobeNewswire
News headline image
BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization
December 02, 2025
From BioNexus Gene Lab Corp.
Via GlobeNewswire
News headline image
BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuard™ MRD Platform as Part of Strategic Alliance with Tongshu Gene
December 01, 2025
From BioNexus Gene Lab Corp.
Via GlobeNewswire
News headline image
12 Industrials Stocks Moving In Wednesday's After-Market Session ↗
November 12, 2025
Via Benzinga
News headline image
BGLC Stock Tumbled Over 13% Today: Why Is VitaGuard Commercialization Agreement Drawing Investor Attention? ↗
November 12, 2025
Via Stocktwits
News headline image
BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization
November 12, 2025
From BioNexus Gene Lab Corp.
Via GlobeNewswire
News headline image
BioNexus Gene Lab Corp. Files $100 Million Shelf Registration and Establishes $20 Million At-the-Market Program to Advance Strategic Growth Opportunities
November 10, 2025
From BioNexus Gene Lab Corp.
Via GlobeNewswire
News headline image
12 Industrials Stocks Moving In Monday's Pre-Market Session ↗
November 03, 2025
Via Benzinga
News headline image
12 Industrials Stocks Moving In Monday's Pre-Market Session ↗
October 20, 2025
Via Benzinga
News headline image
BioNexus Gene Lab Corp Signs Strategic Partnership Term Sheet with BirchBioMed Inc.
October 20, 2025
From BioNexus Gene Lab Corp.
Via GlobeNewswire
News headline image
12 Industrials Stocks Moving In Friday's After-Market Session ↗
September 12, 2025
Via Benzinga
News headline image
These stocks are moving in today's after hours session ↗
September 12, 2025
Via Chartmill
News headline image
12 Industrials Stocks Moving In Friday's Intraday Session ↗
September 12, 2025
Via Benzinga
News headline image
Which stocks are gapping on Friday? ↗
September 12, 2025
Via Chartmill
News headline image
12 Industrials Stocks Moving In Friday's Pre-Market Session ↗
September 12, 2025
Via Benzinga
News headline image
What's Driving the Market Sentiment Around BioNexus Gene Lab? ↗
August 19, 2025
Via Benzinga
News headline image
12 Industrials Stocks Moving In Thursday's Pre-Market Session ↗
July 31, 2025
Via Benzinga
News headline image
Which stocks are experiencing notable movement on Wednesday? ↗
July 30, 2025
Via Chartmill

Frequently Asked Questions

Is BioNexus Gene Lab Corp - Common stock publicly traded?
Yes, BioNexus Gene Lab Corp - Common stock is publicly traded.
What exchange does BioNexus Gene Lab Corp - Common stock trade on?
BioNexus Gene Lab Corp - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for BioNexus Gene Lab Corp - Common stock?
The ticker symbol for BioNexus Gene Lab Corp - Common stock is BGLC on the Nasdaq Stock Market
What is the current price of BioNexus Gene Lab Corp - Common stock?
The current price of BioNexus Gene Lab Corp - Common stock is 1.201
When was BioNexus Gene Lab Corp - Common stock last traded?
The last trade of BioNexus Gene Lab Corp - Common stock was at 10/16/26 01:25 PM ET
What is the market capitalization of BioNexus Gene Lab Corp - Common stock?
The market capitalization of BioNexus Gene Lab Corp - Common stock is 2.16M
How many shares of BioNexus Gene Lab Corp - Common stock are outstanding?
BioNexus Gene Lab Corp - Common stock has 2M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap